NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

suit,

I doubt that anyone is interested in 2016 😶

We are interested in the combo trials that have reached PII, and we are interested in the combo data that we will see in 2025, and we are interested in the additional combo trials that haven’t commenced yet. Even after an initial approval and initial commercialization, combo studies will be ongoing and we will be looking forward to see how big the cell-based platform(s) might become. Commercialization leads to further clinical trials—pembrolizumab was initially commercialized a decade ago, and it has been in ongoing clinical trials ever since…

Checkpoint inhibitors are in clinical trials with TWO patent-fortified novel dendritic cell technologies owned by NWBO: The U.S. DoD awarded a peer-reviewed grant to fund the pembrolizumab combo research at Roswell Park which has reached PII, and the U.S. NIH awarded a continuing peer-reviewed grant to fund the pembrolizumab combo research at UCLA.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927